Guideline of transthyretin-related hereditary amyloidosis for clinicians. - Wikidata - wikimedia - TriplyDB

Guideline of transthyretin-related hereditary amyloidosis for clinicians.

Guideline of transthyretin-related hereditary amyloidosis for clinicians.

http://www.wikidata.org/entity/Q34328734

about

"Red-flag" symptom clusters in transthyretin familial amyloid polyneuropathy Therapeutic Oligonucleotides Targeting Liver Disease: TTR Amyloidosis First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP Evolving landscape in the management of transthyretin amyloidosis Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial Transthyretin-Related Familial Amyloid Polyneuropathy (TTR-FAP): A Single-Center Experience in Sicily, an Italian Endemic Area Genetic determinants of myocardial dysfunction.Cardiac amyloidosis: pathogenesis, clinical context, diagnosis and management options.The Genetic Challenges and Opportunities in Advanced Heart Failure Corino de Andrade disease: mechanisms and impact on reproduction.Update in the diagnosis and management of transthyretin familial amyloid polyneuropathy.An overview of drugs currently under investigation for the treatment of transthyretin-related hereditary amyloidosis.Transthyretin cardiac amyloidosis: pathogenesis, treatments, and emerging role in heart failure with preserved ejection fraction.In vivo detection of nerve injury in familial amyloid polyneuropathy by magnetic resonance neurography.The effect of tafamidis on the QTc interval in healthy subjects.Rapid detection of wild-type and mutated transthyretins.Amyloid Cardiomyopathy in Hereditary Transthyretin V30M Amyloidosis - Impact of Sex and Amyloid Fibril Composition.A New Folding Kinetic Mechanism for Human Transthyretin and the Influence of the Amyloidogenic V30M Mutation.Population diversity of the genetically determined TTR expression in human tissues and its implications in TTR amyloidosis.A Review of Tafamidis for the Treatment of Transthyretin-Related Amyloidosis.Optimizing the management of transthyretin familial amyloid polyneuropathy in Europe: early diagnosis and effective care.Substoichiometric inhibition of transthyretin misfolding by immune-targeting sparsely populated misfolding intermediates: a potential diagnostic and therapeutic for TTR amyloidoses.Amyloid in biopsies of the gastrointestinal tract-a retrospective observational study on 542 patients.Exome Sequencing and Gene Prioritization Correct Misdiagnosis in a Chinese Kindred with Familial Amyloid Polyneuropathy Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin Three cases of systemic amyloidosis successfully diagnosed by subcutaneous fat tissue biopsy of the hip Peripheral Blood Cell Gene Expression Diagnostic for Identifying Symptomatic Transthyretin Amyloidosis Patients: Male and Female Specific Signatures.Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy Tafamidis: a review of its use in familial amyloid polyneuropathy.Liver transplantation in transthyretin amyloidosis: issues and challenges.Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.Progress in the treatment of small fiber peripheral neuropathy.The diversity of mechanisms influenced by transthyretin in neurobiology: development, disease and endocrine disruption.Cardiac amyloidosis: the great pretender.Inherited Structural Heart Diseases With Potential Atrial Fibrillation Occurrence.Drugs for the treatment of peripheral neuropathies.

P2860

Q26776343-E177BB22-B0AE-403F-8A3C-4680578C0734 Q26782089-3F1326E8-5116-4A19-A38F-35E73D99BDC2 Q28071522-95BF0BDF-D7AF-4FFD-A581-E1290E919FA9 Q28076550-CAAED2D3-EB9D-4DCD-A3C0-249812B48040 Q28078350-CFA61D00-6956-4F5E-9D35-9B40315EDC3E Q28086773-7CD798DC-1BA8-465A-AE89-1A6EADE09A1D Q28304712-10706E39-BDA2-4E45-801C-D3F017AC108E Q29248271-3F899310-6BB1-49EA-9720-256E8B4D1DB9 Q30240839-BBC9F88A-3BBE-4A03-BAED-561EB1067F60 Q33168881-839EF47A-D760-44E1-9B91-5006E5B2B75C Q33653498-10954D82-1502-41F7-B9A9-43EE0979A775 Q33807480-D5EC5FEC-2AFD-4F7C-B8A5-5979955BCE0D Q34422510-CDCB4C95-1482-4CC3-94F8-FA229FB14E80 Q34428314-2D3FC5B6-57CF-4A0E-AB36-5478F2FEF715 Q34838524-52C409F9-D844-4FDC-8909-1DA8A6C146A9 Q35119383-C97D1839-441E-4DCD-9A45-6CB2AC6EFF96 Q35684808-EAB10B3B-8FB1-4B81-9B3A-A7D3A16D68C4 Q35765201-7487A882-9326-4E88-AE1E-0407CF07C886 Q35850786-43923EDE-1744-4C78-A39C-19304A681F13 Q36121846-47E2DDCB-2214-4F72-A9F3-20ACFAEE6373 Q36320893-E3D612C3-0494-455B-AD44-EFB219258173 Q36389712-03BBF33D-E734-45B3-958C-F9BE46BD2BF1 Q36538463-2EFF0E0A-FCF3-4319-AE8D-054F36CB7E48 Q36845920-FC17C2B3-D3F3-4899-8408-C581413FEFBE Q36869816-D7229904-DBCE-4483-B55D-0444B5A10B7F Q36925525-65863372-9F77-47E4-AC14-DFFDDBA42C82 Q36981504-1DEAF4B9-6050-4692-87A6-48B1583147FD Q37167777-89620713-827F-4852-B223-50FD34957050 Q37202287-43A06BAD-60AD-405F-BFA4-EFA24CCB8D3D Q37337552-E730B2BE-B709-4639-ABF3-52154906CD83 Q37420577-393290B5-6287-4AC8-987E-04D75E2A7DE2 Q37713229-55494203-2D4B-4E2F-A298-EE6BD64D630D Q38229307-5AD00B18-1247-4953-8B2F-BEBF3442FD78 Q38284506-83A3AD26-1053-420F-A9C2-E4C03F53D753 Q38325612-636DDA54-C74F-4827-841F-B7D59E02C348 Q38349089-4CC54944-DE4C-4E63-B6DB-8B3ACB1F7C81 Q38367420-F9B6E80D-4DC7-47F1-B8BB-3989257CC7EC Q38372860-AFCEB3EA-EE86-4A69-B2A9-884AAB4AAA63 Q38620899-BE9A4DEC-C442-4F92-B52B-3C4FEA9833CE Q38633190-069D1B02-EBF4-49F1-BA01-909129C0C8AD

P2860

Guideline of transthyretin-related hereditary amyloidosis for clinicians.

http://www.wikidata.org/entity/Q34328734

description

2013 nî lūn-bûn

@nan

2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Guideline of transthyretin-related hereditary amyloidosis for clinicians.

@ast

Guideline of transthyretin-related hereditary amyloidosis for clinicians.

@en

Guideline of transthyretin-related hereditary amyloidosis for clinicians.

@nl

type

label

Guideline of transthyretin-related hereditary amyloidosis for clinicians.

@ast

Guideline of transthyretin-related hereditary amyloidosis for clinicians.

@en

Guideline of transthyretin-related hereditary amyloidosis for clinicians.

@nl

prefLabel

Guideline of transthyretin-related hereditary amyloidosis for clinicians.

@ast

Guideline of transthyretin-related hereditary amyloidosis for clinicians.

@en

Guideline of transthyretin-related hereditary amyloidosis for clinicians.

@nl

P1433

Q34328734-3D0E7677-6261-4F8F-894B-509E1D5750EE

P1476

Q34328734-FC79CF8A-B03D-49BA-8967-F51185BF7138

P2093

Q34328734-03F79737-133D-439E-9D76-817FD78A19D2

Q34328734-4DB45A72-4F1D-4091-96C2-7948096412C5

Q34328734-56446CD4-1B98-46AF-9C0A-26EDC41C76ED

Q34328734-572AFE4C-1FB6-41FE-B9E6-87EF5E4B8655

Q34328734-63A11828-8554-4A8F-8D35-23C91504DA10

Q34328734-7696CCAD-A1CE-47B4-8E2B-375736C8365C

Q34328734-BD7CF0E6-C045-4C4F-B5CB-5875E77B49A3

Q34328734-DE677C23-876B-4B9C-A76A-52A22D9C5060

Q34328734-ECCB4DBB-62E2-4E6D-9090-34234DE82E62

P275

Q34328734-B824A798-1272-40C9-A9B5-421D3CEEC07C

P2860

Q34328734-00F855A0-B9D1-44AE-AC58-43EE15F1C61C

Q34328734-0349397C-A14F-4F1B-BFF2-C9902F9FA23E

Q34328734-05730C5B-850E-40A5-AED4-14F7377C703E

Q34328734-0A4C3BEE-DFB2-47C7-B439-27DA9784E730

Q34328734-0CAC9BE9-372F-4623-B23A-1B22C13D6FB0

Q34328734-0E653F43-B39E-4A2D-B10C-8201D6A3F5A4

Q34328734-14B31B32-CB3B-4840-861F-DB1BF390E732

Q34328734-15D6981E-DD35-4E07-878C-C393DDB10D41

Q34328734-179D2B87-1F40-4EA4-BFDB-9B1FE100231E

Q34328734-1CE8F53A-AE8A-46B6-8D5D-A004834890B2

P2888

Q34328734-AB6DB610-F6C7-4B4C-9CE7-62D6243DE366

P304

Q34328734-166BB784-B70D-498F-850B-E171BE09D0B1

P31

Q34328734-A74D719D-F99C-423E-B204-3C47643138DD

P356

Q34328734-25AACEAA-0CE2-47FF-A752-530DB61FB9E8

P478

Q34328734-358109E2-0E6C-4661-855A-3D6B33895A37

P50

Q34328734-7235EBEE-A891-4635-A112-B29BD983D379

Q34328734-7F7508BB-BAAD-43F2-BF71-41E3B1E495C9

Q34328734-92FDF5B3-0A31-4096-BB52-E8FDF2137505

P5008

Q34328734-ACBC5CA9-EE6B-4ACA-8474-3E342C645ADD

P577

Q34328734-7F6E59DC-08CF-4F9E-A885-C8E217063AB2

P5875

Q34328734-17566A5E-C75A-4290-894B-A44427384D2B

P6179

Q34328734-F199460F-EF3F-4434-84A8-FC95A370805E

P698

Q34328734-A3B15FF3-15A8-462C-8E23-6D31D8205D28

P921

Q34328734-0A734C06-FA28-4AE9-AD94-F319FB105A03

Q34328734-BDE36A9F-40A4-48E3-A380-E830954AD897

Q34328734-E39A5DCD-3332-489F-B59C-9639DA429BBD

P932

Q34328734-5638A7DE-4E55-4DEC-B9A7-EF6DCDC5B6BC

P356

P1433

Orphanet Journal of Rare Diseases

P1476

Guideline of transthyretin-related hereditary amyloidosis for clinicians

@en

P2093

Bo-Göran Ericzon

http://www.w3.org/2001/XMLSchema#string

Fabrizio Salvi

http://www.w3.org/2001/XMLSchema#string

Gerard Said

http://www.w3.org/2001/XMLSchema#string

Márcia Waddington Cruz

http://www.w3.org/2001/XMLSchema#string

Shu-ichi Ikeda

http://www.w3.org/2001/XMLSchema#string

Teresa Coelho

http://www.w3.org/2001/XMLSchema#string

Violaine Planté-Bordeneuve

http://www.w3.org/2001/XMLSchema#string

W David Lewis

http://www.w3.org/2001/XMLSchema#string

Yukio Ando

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 2.0 Generic

P2860

Synergy of combined doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models

A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves

Autonomic dysfunction in familial amyloidotic polyneuropathy (FAP)

Biochemical characteristics of variant transthyretins causing hereditary leptomeningeal amyloidosis.

Familial amyloidotic polyneuropathy in Sweden: a pedigree analysis.

Geographical distribution of TTR met30 carriers in northern Sweden: discrepancy between carrier frequency and prevalence rate.

A pedigree analysis with minimised ascertainment bias shows anticipation in Met30-transthyretin related familial amyloid polyneuropathy

Patterns of neuropathy and autonomic failure in patients with amyloidosis.

Significance of the amyloidogenic transthyretin Val 122 Ile allele in African Americans in the Arteriosclerosis Risk in Communities (ARIC) and Cardiovascular Health (CHS) Studies.

Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial

P2888

P304

31

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1750-1172-8-31

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Claudio Rapezzi

P5008

P577

2013-02-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235681177

http://www.w3.org/2001/XMLSchema#string

P6179

1012414979

http://www.w3.org/2001/XMLSchema#string

P698

23425518

http://www.w3.org/2001/XMLSchema#string

P921

P932

3584981

http://www.w3.org/2001/XMLSchema#string